Asan Medical Center

This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without addit…

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…

This study compares aspirin to the blood thinner warfarin in 1058 people who just had a bioprosthetic heart valve replacement. For 6 months after surgery, participants take either daily aspirin or warfarin. The goal is to see if aspirin is just as safe and effective at preventing…

This study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The …

This study looks at whether inhaled nitric oxide can help newborns with a hole in their diaphragm (congenital diaphragmatic hernia) who also have high blood pressure in their lungs. About 40 babies will receive the gas, and doctors will check if their oxygen levels improve within…

This study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to s…

This study will observe 1000 adults having planned brain surgery to see if the thickness of their blood during the operation is linked to problems like infections, kidney injury, or death within 30 days. Researchers will measure blood viscosity and oxygen levels in the brain. The…

This study is testing a new blood test that looks for tiny bits of cancer DNA (called minimal residual disease or MRD) in patients with endometrial or cervical cancer. The goal is to see if this test can find cancer coming back earlier than standard scans or exams. About 600 part…